Inverseon Asthma Drug May Compliment LABAs Published: Feb 24, 2010 SAN FRANCISCO--(BUSINESS WIRE)--Inverseon, Inc. (http://www.inverseon.com) comments on Long Acting Beta-Agonists (LABAs) and INV102CR. Related links BioSpace.com This will open in a new window Email this Facebook Twitter LinkedIn Pinterest Reddit Back to news